(Q44202996)

30 November 2017

Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment (English)

1 reference

30 November 2017

4

Robert W Buchanan

1 reference

30 November 2017

Scott P Baymiller

1

1 reference

30 November 2017

Patricia Ball

series ordinal

2

1 reference

30 November 2017

Robert P McMahon

series ordinal

3

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

30 November 2017

Schizophrenia Research

1 reference

30 November 2017

59

1 reference

30 November 2017

1

1 reference

30 November 2017

49-57

1 reference

Triphasic Randomized Clinical Trial: Comparison of effects on carbohydrate metabolism

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Clozapine and associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Update on the clinical efficacy and side effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

The impact of clozapine treatment on serum lipids in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

The effect of clozapine on glucose metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900158-5

7 January 2021

10.1016/S0920-9964(02)00158-5

Identifiers

DOI

1 reference

30 November 2017

1 reference